Latus Bio closed a $97 million series A to advance an AAV capsid-variant platform with two lead programs: LTS-201 for Huntington’s disease and LTS-101 for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). The company said proceeds fund operations through milestones that include initial clinical data from both programs, positioning Latus as it scales beyond preclinical work.